Postoperative diagnosis of pulmonary actinomycosis in a patient with bronchiectasis ‒ a rare case
DOI:
https://doi.org/10.15584/ejcem.2025.4.11Keywords:
actinomycosis, bronchiectasis, hemoptysis, lobectomy, pulmonary infectionAbstract
Introduction and aim. Pulmonary actinomycosis is a rare chronic infection caused by Actinomyces species, often mimicking tuberculosis, malignancy, or other chronic lung diseases both clinically and radiologically. These similarities frequently lead to diagnostic delays. We present a rare case of pulmonary actinomycosis in a patient with long-standing bronchiectasis who developed acute hemoptysis during anticoagulant therapy.
Description of the case. A 59-year-old woman with a ten-year history of bronchiectasis and recent mechanical aortic valve replacement presented with persistent hemoptysis while on warfarin. Thoracic computed tomography revealed bronchiectatic changes and opacities in the right middle lobe. Bronchoscopy showed bloody, encrusted material, but no definitive diagnosis was made. Due to ongoing symptoms and radiological suspicion of malignancy, an urgent right middle lobectomy was performed. Histopathological analysis confirmed pulmonary actinomycosis, revealing filamentous organisms via PAS, Gram, and Grocott’s staining.
Conclusion. This case highlights the importance of considering pulmonary actinomycosis in patients with bronchiectasis and unexplained hemoptysis, particularly when standard treatment fails. Surgical resection may be essential for both diagnosis and treatment. The case underscores how structural lung disease and anticoagulant use can reveal rare infections otherwise masked by chronic symptoms.
Downloads
References
Afsin E, Kucuk F, Ozcelik H, et al. Coexistence of COVID-19, Pseudomonas, and thoracic actinomycosis in a cystic bronchiectasis case. BMC Infect Dis. 2023;23:203. doi: 10.1186/s12879-023-08215-x
Boot M, Archer J, Ali I. The diagnosis and management of pulmonary actinomycosis. J Infect Public Health. 2023;16(6):490-500. doi: 10.1016/j.jiph.2023.02.004
Barreiro López B, Martinez Palau M, Luizaga L, Sanz-Santos J. Pulmonary Actinomyces Infection Diagnosed by Linear Endobronchial Ultrasonography. Correlation with Histopathological Examination. Open Respir Arch. 2022;4(2):100159. doi: 10.1016/j.opresp.2022.100159
Yi S, Ghimire R, Sporn TA, et al. Pulmonary actinomycosis in a 65-year-old female with poor oral dentition. Diagnostics (Basel). 2024;14(13):1421. doi: 10.3390/diagnostics14131421
Cuzzani G, Fortunati E, Zanoni L, et al. Pulmonary Actinomyces infection mimics lung cancer on [⁶⁸Ga]Ga-FAPI PET/CT. J Nucl Med. 2024;65(7):1161. doi: 10.2967/jnumed.123.267155
Cardoso CG, Freitas C, Gomes I, et al. Enlightening clinical and therapeutic heterogeneity in thoracic actinomycosis: a review in bronchiectasis and non-bronchiectasis patients. Pulm Pharmacol Ther. 2021;71:102078. doi: 10.1016/j.pupt.2021.102078
Ren Y, Ma Q, Zeng X, et al. Salivary microbiota as potential biomarkers for pulmonary nodules. BMC Microbiol. 2024;24(1):132. doi: 10.1186/s12866-024-03280-x
Yuan Y, Hou Z, Peng D, Xing Z, Wang J, Zhang S. Pulmonary Actinomyces graevenitzii infection: case report and review of the literature. Front Med (Lausanne). 2022;9:916817. doi: 10.3389/fmed.2022.916817
Sugihara M, Goto D, Ishiya S, et al. Colloid adenocarcinoma of the lung with concomitant pulmonary actinomycosis: a case report. Respirol Case Rep. 2025;13:e70133. doi: 10.1002/rcr2.70133
Facchin G, Battaglia G, Sartor A, et al. Pulmonary actinomycosis by Actinomyces graevenitzii in two hematologic patients. Mediterr J Hematol Infect Dis. 2023;15(1):e2023034. doi: 10.4084/MJHID.2023.034
Choo JM, Abell GCJ, Thomson R, et al. Impact of long-term erythromycin therapy on the oropharyngeal microbiome and resistance gene reservoir in non-CF bronchiectasis. mSphere. 2018;3(2):e00103-18. doi: 10.1128/mSphere.00103-18
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.




